HC Wainwright Reaffirms Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “neutral” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $1.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential downside of 17.36% from the stock’s current price.

Separately, Bank of America lowered Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $6.00 to $1.00 in a report on Wednesday, October 30th.

Lyell Immunopharma Price Performance

Lyell Immunopharma stock opened at $1.21 on Tuesday. Lyell Immunopharma has a 1-year low of $0.85 and a 1-year high of $3.26. The stock has a market cap of $309.76 million, a PE ratio of -1.53 and a beta of -0.47. The stock’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.70.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.03. The company had revenue of $0.03 million for the quarter. Lyell Immunopharma had a negative return on equity of 33.54% and a negative net margin of 323,792.09%. On average, research analysts expect that Lyell Immunopharma will post -0.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently added to or reduced their stakes in LYEL. Opaleye Management Inc. purchased a new stake in Lyell Immunopharma in the 1st quarter valued at approximately $7,482,000. GSA Capital Partners LLP lifted its position in shares of Lyell Immunopharma by 1,285.5% during the 3rd quarter. GSA Capital Partners LLP now owns 354,815 shares of the company’s stock valued at $490,000 after acquiring an additional 329,205 shares during the period. Caxton Associates LP lifted its position in shares of Lyell Immunopharma by 359.1% during the 1st quarter. Caxton Associates LP now owns 174,657 shares of the company’s stock valued at $389,000 after acquiring an additional 136,611 shares during the period. Invenomic Capital Management LP lifted its position in shares of Lyell Immunopharma by 16.8% during the 1st quarter. Invenomic Capital Management LP now owns 871,525 shares of the company’s stock valued at $1,944,000 after acquiring an additional 125,110 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Lyell Immunopharma by 1.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock valued at $15,013,000 after acquiring an additional 92,594 shares during the period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.